Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Funding Circle on track for 2026 targets after strong first half

(Sharecast News) - Funding Circle delivered a confident outlook to the market on Thursday after reporting solid growth in the first half of 2025. The SME finance platform said that it delivered "strong revenue and profit margin growth" in the first six months of the year, helped by "the strength of our brand, technology and credit decisioning".

The company extended credit of £1.1bn during the period, up 21% from the year before, with balances under management totalling £2.8bn.

The term loans business saw originations of £736m, up from £692m last year, with improved profit margins due to operating leverage and cost actions took in 2024.

Meanwhile, strong growth was also reported in its FlexiPay solution and Cashback credit card, with credit extended now surpassing £1bn since launch.

"I am very pleased with the momentum we have carried into 2025 following our strong performance last year. We saw strong revenue growth with improving profit margins in our streamlined business as we continued to invest in new products," said chief executive Lisa Jacobs.

Jacobs said the company remains confident in hitting its medium-term guidance of £200m in revenue and £30m in pre-tax profit for the next fiscal year.

Shares were 3.7% higher at 134.8p by 1103 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.